While T-DM1 is solely approved for BC, the DESTINY-Lung02 (NCT04644237) and DESTINY-Gastric01 (NCT03329690) trials prompted T-DXd approval for HER2-positive NSCLC and GCs. Here, ERBB2 is linked to non-small cell lung carcinoma.